Kornimate/medical-research-clean huggingface dataset:
effects of weight loss on foot structure and function in obese adults: a pilot study

Conditions: Obesity

Summary: obesity is a serious medical, social, and economic problem and is becoming even greater concern, as the prevalence of overweight and obese individuals has steadily increased over the years. excessive body weight can have a profound influence on lower extremities, including pain, degenerative disease, and compromised quality of life. however, no study to-date has examined the effects of weight change on foot structure and function in individuals over time. the purpose of this study is to determine the effects of weight reduction on foot structure and function in obese adults. improved understanding of the relationship between body weight and foot biomechanics is needed to promote health and healthier lifestyles.


Eligibility criteria:
inclusion criteria: * men and women between the ages of 50 to 75, inclusive * body mass index is ≥ 30 kg/m2 but \< 45 kg/m2 and body weight \< 300 pounds * able to ambulate safely without the use of a walking aid (cane, crutches, or walker) * able to understand the information in the informed consent form and is willing and able to comply with the study-related procedures exclusion criteria: * diabetes, stroke, end stage kidney disease requiring hemodialysis, or widespread malignant disease, gallbladder disease * severe peripheral vascular disease (defined as 1 \< palpable pedal pulse and claudication pain in less than two blocks) * pregnant or nursing, as weight and hormonal changes during pregnancy may affect foot structure and function, which could confound the results of the study. therefore, women who are pregnant or nursing will be excluded from the study. * not willing or able to make the required quarterly follow-up visits * insufficient (corrected) vision to complete the questionnaires * food allergies to the nutrisystem, inc. meal plan used in this protocol * participation in another formal weight loss program within last 6 months * uncontrolled hypertension (systolic blood pressure \> 180 or diastolic blood pressure \> 100 mmhg). participants on medication treating hypertension for at least three months are allowable. * known atherosclerotic cardiovascular disease * history of congestive heart failure * history of a non-skin malignancy within the previous 5 years * any major active rheumatologic, pulmonary, hepatic, renal, dermatologic disease or inflammatory condition

Keywords: obesity foot pain
an electronic decision support tool to improve outpatient asthma care

Conditions: Asthma

Summary: the children's hospital of philadelphia's ambulatory network uses an electronic health record (ehr) to document clinical information. using the ehr, a clinical decision support tool will be designed to help the primary care physician's in caring for children with asthma. the goal will be to improve the primary care physician's use of the national institutes of health guidelines for the best care for asthma. to study this ehr decision support tool, it will be introduced into 5 practices while 5 other practices will have the existing asthma care information. it will be determined whether the physicians in the practices with the decision support tool are better at following the asthma guidelines. if the decision support tool works...then it will be offered to others to use with their ehr systems.

national asthma education and prevention program guidelines (naepp) exist, but are under used in primary care. in addition, implementation of the guidelines has been shown to be vary according to the location of practice and other contextual factors. the children's hospital of philadelphia pediatric research consortium (perc), a practice-based research network will determine whether an innovative clinical decision support system embedded in an existing electronic health record (ehr) will improve provider adherence to the existing naepp guidelines. after receiving a standardized education module based on naepp guidelines, 10 primary care pediatric practices (both urban and suburban) will be randomized to receive either a passive ehr (control sites) or an interactive decision support sytem (intervention sites). the primary outcome of interest will be the proportion of patient son appropriate asthma controller medication compared over time. secondary outcomes include the proportion of asthma patients with: 1) an updated asthma action plan 2) documentation of spirometry performed (6 to 17years) and 3) an updated problem list reflecting current asthma severity. after hours calls to providers and types of office visits related to to asthma will be tracked. contextual factors at the clinic and patient level will be examined to assess their association with the outcomes of interest. in addition, measurement of asthma-related quality of life and missed school and work in a sample of 200 subjects from each group will be performed if shown to be successful, this type of clinical decision support, embedded within the ehr, has the potential to be a powerful tool to improve the implementation of asthma guidelines and clinical practice guidelines for other conditions and illnesses.

Eligibility criteria:
inclusion criteria: * children with the diagnosis of asthma * children enrolled in one of 10 selected primary care practices in the perc practice-based research network
different home exercise programs in neck pain

Conditions: Neck Pain; Exercise Training

Summary: purpose: the aim of this study was to compare the effects of two different home exercise methods on exercise compliance, neck pain and neck disability in individuals with neck pain. material and metods: the study, carried out between february 2018 and may 2018 at istanbul arel university vocational school, was performed with 60 people aged 25-60 years who were suffering from neck pain in academic and administrative staff. the cases were randomly divided into two groups. in group 1, the case was given home exercise method (b.m.e.y) with printed materials whereas group 2 was given exercise with home exercise method (v.h.e.y) with video phone reminder. pain intensity was evaluated before and after exercise with 'visual analog scale' (vas), whereas the level of neck disability was evaluated before and after exercise with 'neck pain and disability score' (npds). the obtained results were analyzed using appropriate statistical methods.

both groups were prescribed the same type of exercise, duration of exercise and number of repetitions. group 1 completed the exercise program and marked the exercise attendance schedule. at the end of the program, these charts were collected from the subjects and the continuity was evaluated. the group marked the exercises completed with 2 phone app. in the program used, exercise continuity of the cases was evaluated as days. exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.

Eligibility criteria:
inclusion criteria: * complaint of neck pain, * being between 25-60 years of age exclusion criteria: * taking painkillers regularly, * undergoing any neck surgery and severe trauma, * presence of any diagnosed neck disease
ganglioside and ibd

Conditions: Inflammatory Bowel Diseases

Summary: context. inflammatory bowel disease (ibd) is a chronic and debilitating disorder. novel treatment strategies aimed to resolve intestinal inflammation and induce disease remission are necessary. dietary gangliosides are safe for consumption, bioavailable, and have shown clinical benefit in patients with inflammatory intestinal disease. objectives. the primary objective is this study is to determine the efficacy of dietary ganglioside in improving disease activity indices in pediatric patients with ibd. secondary objectives include demonstrating the effectiveness of dietary ganglioside for improving quality of life, improving intestinal integrity, and reducing inflammation. study design. intervention: controlled trial (pilot). participants. inclusion criteria: aged 9-21 years, diagnosis of ulcerative colitis (uc) or ileal or colonic crohn disease (cd), active disease. exclusion criteria: pregnancy, inadequate liver or renal function, active infectious disease, previous bowel resection, disease remission, drug/alcohol abuse, other serious medical conditions, indeterminate colitis. study intervention. patients with ibd (n=48) will be allocated to consume ganglioside treatment or placebo daily for 10 weeks. treatment group will consume five grams of buttermilk powder daily or anhydrous milk fat. outcome measures. the primary outcome is the disease activity index: pediatric crohn's disease activity index (pcdai) or pediatric ulcerative colitis activity index (pucai). secondary outcomes include: quality of life (impact-iii questionnaire), intestinal permeability (lactulose/mannitol urinary assay), c-reactive protein (crp; blood exam), calprotectin (fecal exam). expected outcomes. relative to the placebo group, the treatment group will have improved disease activity indices, quality of life, and intestinal integrity over the 10-week study period. the treatment group will also show reduction in inflammation and calprotectin relative to the placebo group.


Eligibility criteria:
inclusion criteria: 1. participants age 9-21 years 2. mild-moderate ibd defined by improvecarenow (icn) physician global assessment (pga); or severe ibd defined by icn pga if stable for at least 120 days 3. ileal, ileocolonic, colonic location of disease exclusion criteria: 1. pregnancy 2. previous bowel resection 3. non-ileocolonic location of disease 4. inadequate liver or renal function 5. on prescription medication for active infectious disease 6. drug/alcohol abuse 7. other serious medical conditions
effects of 2 different duration of albendazole therapy in patients with neurocysticercosis in brain ≤ 5 lesions on ct

Conditions: Neurocysticercosis

Summary: comparing the effect of two different duration of same drug albendazole in patients with neurocysticercosis less than or equal to 5 lesions on ct head at the end of 6 months.

the trial will be comparing the effectiveness of short and long duration of albendazole ie 7 and 28 days therapy in patients with parenchymal neurocysticercosis in terms of complete resolution or calcification of cyst on ct head at the end of 6 months after starting albendazole

Eligibility criteria:
inclusion criteria: * age 2-18 years. * number of parenchymal lesions: upto 5\* * stages of cysticerci at which albendazole treatment is effective * vesicular stage * colloid vesicular stage * granular nodular stage exclusion criteria: * cysticercotic encephalitis * calcified cyst * hydrocephalus * intraventricular cyst * subarachnoid cyst * ophthalmic cysticercosis * no of cysts \>5 * known allergy to benzimidazole class of compound which includes anaphylaxis, hypotension, severe skin reactions . * features of raised ict (papilloedema, hyperventilation, hypertension, tonic posturing, b/l 6th nerve palsy, features of midline shift on ct/mri) * critically sick (respiratory failure, cardiovascular instability) * already received albendazole or praziquantel or steroid therapy

Keywords: parenchymal neurocysticercosis upto five lesions
a randomized clinical trial of shenbai granules in reducing recurrence of colorectal adenoma

Conditions: Gastroenterology

Summary: this study evaluates shenbai granules in prevention of colorectal adenomatous polyp recurrence after colonoscopy.half of participants will receive shenbai granules,while the other half will receive a placebo.

there is no internationally recognized standard treatment for the prevention of recurrence of colorectal adenomatous polyps. based on tcm,previous studies have found that shenbai granules can significantly reduce the recurrence and deterioration rate of colorectal adenomatous polyps,reduce the proliferation of tumor cells and promote apoptosis of tumor cells.

Eligibility criteria:
inclusion criteria: 1. meet the colorectal adenomatous polyp diagnosis. 2. polypectomy under colonoscopy;including snare polypectomy,endoscopic mucosal resection,endoscopic submucosal dissection. 3. aged 18-70. 4. sign informed consent. exclusion criteria: 1. colonoscopy was reported, but no pathological findings were found. 2. patients with hereditary polyposis. 3. there is reliable evidence that the tumor has infiltrated into the intrinsic mucosal layer,or deep infiltration under the mucosa is suspected. 4. combined with colorectal malignancy or previous history of colorectal malignancy. 5. colonoscopy highly suggests inflammatory bowel disease. 6. pregnant and lactating women. 7. women who recently have a planning pregnant programme. 8. prone to bleeding and using anticoagulants. 9. patients with severe cardiovascular,pulmonary and cerebrovascular diseases and liver and kidney dysfunction (alt and ast are two times higher than the upper limit of normal value in the laboratory of the center;serum creatinine and urea nitrogen are 1.5 times higher than the upper limit of the normal value in the laboratory of the center. 10. unstable vital signs. 11. suspect or have a history of alcohol or drug abuse. 12. frequent changes in the working environment or other circumstances are likely to cause loss of interview. 13. drugs (aspirin, folic acid, vitamin d, calcium) with potential to treat colorectal adenomas have been used. 14. those who are participating in other clinical trials.

Keywords: colorectal adenoma clinical curative effect complementary and alternative medicine
hypersensitivity pneumonitis: disease progression characterization

Conditions: Hypersensitivity Pneumonitis

Summary: evita is a multicentric latin-american prospective cohort on chronic hypersensitivity pneumonitis. evita's objective is to identify phenotypes and/or endotypes associated with different disease trajectories measured primarily by forced vital capacity (fvc) during a 24 month follow-up period. other secondary measures of disease progression will also be investigated such as imaging, time to death or lung transplantation, and patient-reported outcomes


Eligibility criteria:
inclusion criteria: 1. adult outpatient subjects (18 years old or older) that fulfill the 2020 ats/jrs/alat diagnostic criteria of hp of at least moderate confidence (70% confidence or more). 2. willingness to undergo the evaluations proposed in this protocol 3. hp diagnosis within the last 24 months 4. presence of radiological or histological fibrosis: 4.a. radiological fibrosis consists of unequivocal fine or coarse reticulation with architectural lung distortion and/or traction bronchiectasis and/or honeycomb. 4.b. unequivocal histopathological fibrosis evidenced on lung specimens exclusion criteria: 1. pregnancy 2. presence of established connective tissue disease 3. severe comorbidity impacting on the respiratory system as judged by the attending physician (ex. congestive heart failure, neoplasm, post-covid-19 sequelae) 4. use of supplemental oxygen at rest 5. dyspnea mmrc 4 (too breathless to leave the house or breathless when dressing or undressing) 6. unequivocal emphysematous pattern of hp on hrct 7. unequivocal pleuro-parenchymal fibroelastosis on the hrct 8. significant pulmonary arterial hypertension: 8.a. signs of right ventricular failure by echodopplercardiogram or 8.b. cardiac index \< 2l/min/m2 or right heart catheterism

Keywords: hypersensitivity pneumonitis pulmonary fibrosis interstitial lung disease
p3 study comparing once daily sb204 and vehicle gel in acne

Conditions: Acne Vulgaris

Summary: this is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the us.

this is a double-blind, placebo controlled study in subjects with moderate to severe acne. subjects who satisfy the entry criteria will be randomized to sb204 4% qd or vehicle gel qd in a 1:1 ratio. efficacy assessments will include investigator global assessments (iga) and inflammatory and non-inflammatory lesion counts. subjects will return for post-baseline evaluation at weeks 2, 4, 8, and 12/early termination (et).

Eligibility criteria:
inclusion criteria: * moderate to severe acne * minimum of 25 and no more than 70 non-inflammatory lesions (open and closed comedones) on the face * minimum of 20 and no more than 40 inflammatory lesions (papules and pustules) exclusion criteria: * women of child-bearing potential who are pregnant, nursing, considering becoming pregnant * any dermatologic condition that could interfere with clinical evaluations including severe, recalcitrant cystic acne
intra-arterial tenecteplase during first thrombectomy attempt for acute stroke (bretis-tnk ii)

Conditions: Stroke, Ischemic

Summary: a recent pilot study suggests intra-arterial tenecteplase (tnk) during the first pass of endovascular treatment (evt) seems safe, may increase first-pass reperfusion and good outcome in acute ischemic stroke (ais) patients with large vessel occlusion (lvo). the study aimed to determine the efficacy and safety of intra-arterial tnk administration during evt in ais-lvo patients.


Eligibility criteria:
inclusion criteria: * age ≥18 years; * stroke patient with large vessel occlusion (internal carotid artery, m1 or m2 of middle cerebral artery, basilar artery, or intracranial segment of vertebral artery) who meets criteria for endovascular treatment within 24 hours of stroke onset; * the modified rankin scale (mrs) score before onset ≤ 2; * aspects 6 or greater on ct * signed informed consent. exclusion criteria: * hemorrhagic stroke; * tandem occlusion; * coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (\<100000/mm3); * severe hepatic or renal dysfunction, increase in alt or ast (more than 2 times of upper limit of normal value), elevated serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis; * severe uncontrolled hypertension (systolic blood pressure over 200mmhg or diastolic blood pressure over 110 mmhg); * patients with contraindication or allergic to any ingredient of drugs in our study; * pregnancy, or plan to get pregnant or during active lactation; * suspected septic embolus or infective endocarditis * the estimated life expectancy is less than 6 months due to other serious diseases; * other conditions unsuitable for this clinical study as assessed by researcher.
multifocal high add contact lens proof of concept trial

Conditions: Presbyopia

Summary: the purpose of this study is to evaluate the visual performance of a new multifocal high add contact lens compared to the currently-marketed air optix® aqua multifocal (aoamf) high add contact lens.


Eligibility criteria:
inclusion criteria: * must sign an informed consent document; * presbyopic and require at least 2.25 diopters (d) spectacle add power; * current or previous soft contact lens wearer; * not able to achieve monocular near visual acuity (va) 0.2 logarithm of the minimum angle of resolution (logmar) \[early treatment of diabetic retinopathy study (etdrs)\] or better in each eye with air optix® aqua multifocal (aoamf) high add contact lenses; * willing and able to wear multifocal contact lenses in both eyes within the available range of powers for this trial; * manifest cylinder less than or equal to 1.00 d; * able to achieve best corrected visual acuity (bcva) of 20/25 or better in each eye at distance (as determined by manifest refraction); * other protocol-defined inclusion criteria may apply. exclusion criteria: * any anterior segment infection, inflammation, disease, or abnormality that contraindicates contact lens wear within 6 months prior to enrollment, as determined by the investigator; * any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator; or any use of topical ocular medications that would require instillation during contact lens wear; * any history of herpetic keratitis; * history of corneal or refractive surgery, irregular cornea or unilateral pseudophakia; * biomicroscopy findings (except for corneal vascularization) that are moderate (grade 3) or severe (grade 4); * corneal vascularization that is mild (grade 2) or higher; * a pathologically dry eye that precludes contact lens wear; * monocular (only 1 eye with functional vision); * anisometropia ≥ 1.50 d (contact lens distance prescription); * clinically significant (\> 1 millimeter) anisocoria; * history of intolerance or hypersensitivity to any component of the investigational products; * concurrent participation in a contact lens or contact lens care product clinical trial within the previous 30 days; * eye injury or ocular or intra-ocular surgery within 6 months prior to enrollment; * any ocular or systemic medical condition that may, in the opinion of the investigator, preclude safe administration of the study lenses or affect the results of this study; * other protocol-defined exclusion criteria may apply.

Keywords: contact lens presbyopia multifocal
cmv intensive care units

Conditions: CMV Infection

Summary: prospectively assessment of cmv viremia by real-time polymerase chain reaction (pcr) in a broad cohort of consecutive immunocompetent adults admitted to a major heart surgery intensive care unit (mhs-icu) with the goal of determining the epidemiology, risk factors, and clinical significance of cmv infection.


Eligibility criteria:
inclusion criteria: * agreeing to participate in the study * age of at least 18 years * admission to the mhs-icu for at least 72 hours exclusion criteria: * inability to give informed consent * age younger than 18 years * aids * pregnancy * organ or bone marrow transplant, receipt of immunosuppressive therapy including corticosteroids within 30 days, and cancer or hematologic malignancy treated with radiotherapy or chemotherapy

Keywords: cytomegalovirus critical patient icu immunocompetent clinical suspicion risk factors